What we develop
Sensorion’s mission is to offer innovative therapeutic solutions that provide long-term improvements to the lives of patients suffering from, or at risk of, inner ear disorders. In striving to fill this significant unmet medical and social need, we are continuously developing and optimizing our pipeline, mobilizing our in-house technology platform, scientific expertise, and network of experts.
| Program | Indication | Discovery | In vivo PoC | Pre-clinical | Phase 1 | Phase 2 | Phase 3 | Next milestones |
|---|---|---|---|---|---|---|---|---|
| TREAT | ||||||||
| SENS-401 SSNHL | Sudden Sensorineural Hearing Loss | 100 | 100 | 100 | 100 | 100 | 0 | Exploring partnering options |
| PREVENT | ||||||||
| SENS-401 CIO | Cisplatin-Induced Ototoxicity | 100 | 100 | 100 | 100 | 30 | 0 | Safety and efficacy preliminary data Septembre 2024 |
| SENS-401 Cochlear | Hearing preservation after cochlear implantation | 100 | 100 | 100 | 100 | 60 | 0 | Primary endpoint readout H1 2024 |
| RESTORE | ||||||||
| OTOF-GT (SENS-501) | Otoferlin deficiency | 100 | 100 | 100 | 100 | 2 | 0 | First Patient Communication H2 2024 |
| GJB2-GT | GJB2 related early presbycusis | 100 | 100 | 10 | 0 | 0 | 0 | IND-enabling preclinical activities |
| GJB2-GT | Pediatric progressive GJB2 related hearing loss | 100 | 100 | 10 | 0 | 0 | 0 | IND-enabling preclinical activities |
| GJB2-GT | Congenital GJB2 related hearing loss | 100 | 100 | 10 | 0 | 0 | 0 | IND-enabling preclinical activities |
PRODUCTS
04 67 20 77 30
Go to the description